(Alliance News) - The board of GVS Spa on Thursday approved the financial results for the first quarter of 2026, which closed with a normalized net profit of EUR10.7 million.

During the period, GVS recorded consolidated revenue of EUR105 million, down 2.1% at current exchange rates but up 3.9% at constant exchange rates compared to the same period in 2025.

The Healthcare & Life Sciences division generated revenue of EUR72.1 million, up 3.5% at constant exchange rates, accounting for 68.7% of the total, with positive contributions from MedTech, Transfusion Medicine, and Life Sciences. The Energy & Mobility division recorded revenue of EUR13.6 million, down slightly by 0.5% at constant exchange rates, while the Safety division posted revenue of EUR19.3 million, an 8.6% increase at constant exchange rates.

Normalized EBITDA rose by 0.3% compared to the first quarter of 2025, with a margin on revenue of 24.6%, an improvement over the 24.1% recorded the previous year, supported by profitability recovery measures.

Normalized EBIT stood at EUR17.2 million, down 8.1% from EUR18.8 million in the first quarter of 2025, with a margin of 16.4%, weighed down by increased depreciation and amortization on tangible assets and right-of-use assets.

Normalized net financial expenses fell to EUR2.7 million from EUR2.8 million in the same period of 2025, excluding foreign exchange components, primarily due to a reduction in contractual interest rates.

The net financial position as of March 31, 2026, was negative at EUR249.8 million, a deterioration of EUR9.7 million compared to the end of 2025.

The company confirmed its guidance for the 2026 financial year, as communicated during the approval of the 2025 financial statements.

GVS shares were up 1.3% at EUR4.28 on Thursday.

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2026 Alliance News IS Italian Service Ltd. All rights reserved.